$4.62
0.00%
Nasdaq, Oct 03, 10:00 pm CET
ISIN
US90466Y1038
Symbol
UNCY

Unicycive Therapeutics Inc Stock price

$4.62
+0.33 7.69% 1M
-1.28 21.69% 6M
-3.32 41.83% YTD
+0.82 21.58% 1Y
-1.38 23.00% 3Y
-53.88 92.10% 5Y
-53.88 92.10% 10Y
-53.88 92.10% 20Y
Nasdaq, Closing price Fri, Oct 03 2025
+0.00 0.00%
ISIN
US90466Y1038
Symbol
UNCY
Industry

Key metrics

Basic
Market capitalization
$81.6m
Enterprise Value
$59.3m
Net debt
positive
Cash
$22.3m
Shares outstanding
14.1m
Valuation (TTM | estimate)
P/E
- | negative
P/S
- | 15.4
EV/Sales
- | 11.2
EV/FCF
negative
P/B
5.0
Financial Health
Equity Ratio
23.5%
Return on Equity
-509.0%
ROCE
-
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
- | $5.3m
EBITDA
- | $-42.4m
EBIT
- | $-32.6m
Net Income
- | $-25.0m
Free Cash Flow
$-33.2m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -32.2%
EBIT
- | -1.4%
Net Income
- | 33.9%
Free Cash Flow
-53.2%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -798.8%
EBIT
-
Net
- | -470.5%
Free Cash Flow
-
More
EPS
-
FCF per Share
$-2.4
Short interest
8.9%
Employees
23
Rev per Employee
$0.0
Show more

Is Unicycive Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

Unicycive Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Unicycive Therapeutics Inc forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a Unicycive Therapeutics Inc forecast:

Buy
93%
Hold
7%

Financial data from Unicycive Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 12 12
41% 41%
-
- Research and Development Expense 20 20
55% 55%
-
-32 -32
55% 55%
-
- Depreciation and Amortization 0.02 0.02
100% 100%
-
EBIT (Operating Income) EBIT -32 -32
55% 55%
-
Net Profit -38 -38
20% 20%
-

In millions USD.

Don't miss a Thing! We will send you all news about Unicycive Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Unicycive Therapeutics Inc Stock News

Neutral
PRNewsWire
2 days ago
NEW YORK , Oct. 3, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between March 29, 2024 and June 27, 2025, both dates inclusive (the "Class Period"), of the important October 14, 2025 lead plaintiff deadline. So what: If you purchased Unicycive securities during the Class Period you ma...
Neutral
GlobeNewsWire
2 days ago
NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between March 29, 2024 and June 27, 2025, both dates inclusive (the “Class Period”), of the important October 14, 2025 lead plaintiff deadline.
Neutral
PRNewsWire
2 days ago
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Unicycive between March 29, 2024 and June 27, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (...
More Unicycive Therapeutics Inc News

Company Profile

Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.

Head office United States
CEO Shalabh Gupta
Employees 23
Founded 2016
Website unicycive.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today